Work

Dupilumab Treatment in Pemphigus: A Report of Three Cases and Literature Review

Year: 2025

Type: article

Abstract: ABSTRACT Pemphigus vulgaris (PV) and foliaceus (PF) are rare autoimmune blistering diseases traditionally treated with systemic corticosteroids, immunosuppressants, intravenous immunoglobulins, and rituximab. Nonetheless, a subset of patients remains refractory or has contraindications to these conventional therapies. We present three cases of PV and PF treated with dupilumab. Two patients exhibited rapid clinical improvement. However, one patient with pemphigus foliaceus showed no response to dupilumab treatment, leading to its discontinuation. Recent reports have documented nine cases of pemphigus treated with dupilumab (six PV and three PF). The cases showed a rapid clinical improvement, although dosing regimens varied. One patient discontinued treatment due to lack of efficacy after 4 weeks of follow‐up. Dupilumab appears to be a promising therapeutic alternative for patients with PV and PF. Further studies are needed to evaluate its efficacy.

Source: JEADV Clinical Practice

DOI: 10.1002/jvc2.70209

Authors: José Javier Mateos Rico, Marta Gutiérrez Pascual, María Dolores Caro Gutiérrez, Cristina Marcos Rodríguez, Javier de Quadros Malagón, Francisco Javier Vicente Martín

Institutions: Universidad Rey Juan Carlos, Hospital Universitario Rey Juan Carlos

Language: English

Topic: Autoimmune Bullous Skin Diseases

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,310